Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360737 · ClinicalTrials.gov registry record · Phase 1
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
A Phase 1 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00360737: Completed Phase 1 study, sponsored by Emergent BioSolutions.
NCT00360737 is a Phase 1 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00360737, a Phase 1 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety of the 7 Botulinum Antitoxin Serotypes derived from horses using various laboratory measurements, clinical examinations and adverse events. In addition, following intravenous (injected into the vein) administration assessing how much 7 Botulinum Antitoxin remains in the body.
Primary Outcome
Number of subjects with AEs and severity of AEs up to Day 28
Interventions
- BIOLOGICAL Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT00360737 record still lists
NCT00360737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 1 intervention - of which Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) is the first listed.
NCT00360737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00360737 about?
NCT00360737 is a clinical study titled "Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses". The primary purpose of the study is to evaluate the safety of the 7 Botulinum Antitoxin Serotypes derived from horses using various laboratory measurements, clinical examinations and adverse events. In addition, following intravenous (injected into the vein) administration assessing how much 7 Botul...
What is the current status of trial NCT00360737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-07. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00360737?
The interventions under investigation include: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00360737?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00360737's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia